263 - DEFINING CLINICALLY SIGNIFICANT IMMUNOLOGIC RESPONSE THRESHOLDS TO HAART

264 - HIV-1 RESERVOIR EVOLUTION IN THE MONTREAL PRIMO-INFECTION COHORT

265 - LONG TERM IN VIVO PERSISTENCE OF D30N MUTATION IN THE ABSENCE OF NELFINAVIR PRESSURE

266 - TIME TO LOOK IN YOUR PATIENT'S MOUTH

267 - SUCCESSFUL ANTIRETROVIRAL SEQUENCING OF PATIENT-DERIVED HIV-1 ISOLATES CONTAINING A K65R MUTATION

268 - COMPARISON OF ONCE-DAILY HAART IN INJECTION DRUG USERS (IDUs) AND NON-IDUs FOR THE TREATMENT OF HIV-1 INFECTION

269 - A WIDE CHOICE OF INSTRUMENTATION BUT ONLY A FEW VALID OPTIONS FOR CD4 T-CELL ENUMERATION

270 - A MODEL FOR EVALUATING THE EFFICACY OF HAART AS A FUNCTION OF ADHERENCE TO METHADONE IN HIV-INFECTED IDUs RECEIVING DIRECTLY OBSERVED THERAPY (DOT) IN A METHADONE (MET) MAINTENANCE PROGRAM

271 - "SMART" GATING STRATEGY FOR CD4 T-CELL ENUMERATION: AN AFFORDABLE UNIVERSAL APPLICATION

272 - NO CHANGES REQUIRED IN METHADONE DOSE WHEN STARTING OR CHANGING LOPINAVIR- OR ATAZANAVIR-BASED HAART REGIMENS IN HIV-INFECTED INJECTION DRUG USERS (IDUs)

273 - VIROLOGIC EFFICACY OF TENOFOVIR (TDF) AND DIDANOSINE (DDI) AS COMPONENTS OF NNRTI AND PI-BASED HAART IN TREATMENT-EXPERIENCED PATIENTS

274 - EFFICACY OF SUBSTITUTION OF EFAVIRENZ FOR PROTEASE INHIBITORS IN VIROLOGICALLY SUPPRESSED PATIENTS HAVING FAILED A PRIOR PI BASED REGIMEN

275 - COST OF ADMINISTERING ANTIRETROVIRAL EXPANDED ACCESS PROGRAMS (EAPs) IN NORTHERN ALBERTA

276 - PROGNOSTIC VALUE OF INTERLEUKIN-7 IN HIV-INFECTED CHILDREN

277 - THE USE OF GLOBAL RISK ASSESSMENT (GRA) TO EVALUATE HYPERLIPIDEMIA IN HIV INFECTED PATIENTS

278 - LACK OF EFFECT OF ANTIRETROVIRALS ON LIVER INFLAMMATION OR FIBROSIS IN HIV/HCV COINFECTED PATIENTS

279 - BCL-2 EXPRESSION MAY ADVERSELY AFFECT OUTCOME IN HIV-ASSOCIATED DIFFUSE LARGE B CELL LYMPHOMA; RITUXIMAB AND HAART WITH CHEMOTHERAPY MAY ABROGATE THIS EFFECT

280 - HOW MUCH HAS HAART DECREASED THE INCIDENCE OF HIV-RELATED MALIGNANCIES? – THE SOUTHERN ALBERTA CLINIC (SAC) EXPERIENCE

281 - INTERNET-BASED POST-MARKETING SURVEILLANCE SYSTEM FOR PATIENTS WITH HIV/AIDS: A PILOT PROJECT

282 - THE IMPACT OF MULTIPLE AIDS DEFINING ILLNESSES ON THE MORBIDITY AND MORTALITY OF HIV INFECTED INDIVIDUALS

283 - A RETROSPECTIVE STUDY ASSESSING THE AFFECT OF NEWER LIPID LOWERING AGENTS (LLAS) ON THE LIPID PROFILES OF HIV-INFECTED PATIENTS TAKING COMBINATION ANTIRETROVIRAL THERAPY AS COMPARED TO OLDER LLAS

284 - DURATION AND OUTCOMES OF SECOND AND SUBSEQUENT ANTIRETROVIRAL THERAPY IN HIV-HCV CO-INFECTION

285 - RELATIVE IMPACT OF ESOPHAGEAL CANDIDIASIS (EC) VERSUS OTHER AIDS EVENTS IN THE OPTIMA TRIAL

286 - EVALUATION OF THE CAVIDI EXAVIR LOAD (v2), AN ALTERNATIVE TO

287 - THE IMPACT ON VIROLOGIC OUTCOME OF ATAZANAVIR WITH AND WITHOUT TENOFOVIR IN ANTIRETROVIRAL EXPERIENCED PATIENTS

288 - PARTICIPATION IN HIV DRUG TRIALS: A SYSTEMATIC REVIEW AND META-TRIANGULATION

289 - DUAL THERAPY IN THE ERA OF TRIPLE THERAPY

290 - RARE OCCURRENCE OF RENAL TOXICITY WHEN RETROSPECTIVELY EVALUATING THE USE OF TENOFOVIR DF IN 2 CLINICAL PRACTICES

291 - HIV/AIDS AND AEROBIC EXERCISE: RESULTS OF A COCHRANE COLLABORATION SYSTEMATIC REVIEW

292 - STRATIFICATION OF RISK FOR MORTALITY BY BASELINE CD4 CELL COUNTS IN HEPATITIS C POSITIVE AND NEGATIVE INDIVIDUALS INITIATING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)

293 - RENAL SAFETY PROFILE OF TENOFOVIR DF (TDF) + EMTRICITABINE (FTC) COMPARED TO FIXED-DOSE ZIDOVUDINE/LAMIVUDINE (CBV) IN COMBINATION WITH EFAVIRENZ (EFV) IN ANTIRETROVIRAL-NAïVE PATIENTS

294 - IMPROVEMENT IN LIPID PARAMETERS ASSOCIATED WITH SWITCH FROM STAVUDINE (D4T) TO TENOFOVIR DF (TDF) IN HIV-INFECTED PATIENTS PARTICIPATING IN GS 903E

295 - IDENTIFICATION AND FOLLOW UP OF ABACAVIR-RELATED TOXICITIES WHICH JUSTIFY ITS SUBSTITUTION FOR TENOFOVIR DF (24WK DATA FROM THE RECOVER COHORT)

296 - IDENTIFICATION AND FOLLOW UP OF ADVERSE EVENTS RELATED TO AZT USE THAT CAUSE ITS SUBSTITUTION FOR TENOFOVIR DF IN CLINICAL PRACTICE (48WK DATA FROM THE RECOVER COHORT)

297 - COMPARATIVE EVALUATION OF RENAL FUNCTION (RF) IN HIV-INFECTED, TREATMENT NAIVE PATIENTS OF AFRICAN AMERICAN (AA) DESCENT RECEIVING HAART REGIMENS CONTAINING EITHER TENOFOVIR DF (TDF) OR ZIDOVUDINE (AZT)

298 - IMPROVEMENT OF DYSLIPIDEMIA IN PATIENTS SWITCHING FROM DIDANOSINE TO TENOFOVIR. FINAL 48WK DATA FROM THE RECOVER COHORT